SI-BONE, Inc. (NASDAQ:SIBN) Shares Acquired by Sterling Capital Management LLC

Sterling Capital Management LLC grew its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 12.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 120,795 shares of the company’s stock after purchasing an additional 13,828 shares during the period. Sterling Capital Management LLC owned about 0.29% of SI-BONE worth $1,694,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. FMR LLC boosted its holdings in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after buying an additional 1,198 shares during the period. Mainstream Capital Management LLC acquired a new position in SI-BONE in the 4th quarter worth approximately $53,000. R Squared Ltd purchased a new position in SI-BONE during the 4th quarter worth approximately $73,000. KLP Kapitalforvaltning AS acquired a new stake in SI-BONE during the 4th quarter valued at $97,000. Finally, Proficio Capital Partners LLC purchased a new stake in shares of SI-BONE in the fourth quarter valued at $155,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Insider Buying and Selling at SI-BONE

In related news, SVP Michael A. Pisetsky sold 3,128 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now owns 244,878 shares in the company, valued at $3,462,574.92. This trade represents a 1.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares in the company, valued at $4,026,453.25. This trade represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,776 shares of company stock valued at $96,644 in the last 90 days. 3.90% of the stock is currently owned by company insiders.

SI-BONE Stock Down 0.1 %

NASDAQ SIBN opened at $13.36 on Tuesday. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16. The stock has a market cap of $567.17 million, a PE ratio of -14.52 and a beta of 1.02. The firm has a 50-day simple moving average of $15.55 and a 200 day simple moving average of $14.64. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

SI-BONE (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The company had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. On average, research analysts forecast that SI-BONE, Inc. will post -0.78 EPS for the current year.

Analysts Set New Price Targets

SIBN has been the topic of several research analyst reports. Needham & Company LLC lifted their target price on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 25th. Finally, Truist Financial reiterated a “buy” rating and issued a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $24.40.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.